Andrea I Mcclatchey

List of Publications by Year
in descending order

44	7,119	136885	243529
papers	citations	32 h-index	44 g-index

63	63	63	8351
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EPHecting cell contact by increasing cortical tension. Journal of Cell Biology, 2021, 220, .	2.3	1
2	Uncovering mutation-specific morphogenic phenotypes and paracrine-mediated vessel dysfunction in a biomimetic vascularized mammary duct platform. Nature Communications, 2020, 11, 3377.	5.8	30
3	EGFR-induced cytoskeletal changes drive complex cell behaviors: The tip of the iceberg. Science Signaling, 2018, 11, .	1.6	12
4	Proliferation-independent role of NF2 (merlin) in limiting biliary morphogenesis. Development (Cambridge), 2018, 145, .	1.2	15
5	Cellâ€“Cell Contact and Receptor Tyrosine Kinase Signaling. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029215.	2.3	23
6	Actinâ€™ Up to Stop SNFin Out TEAD. Developmental Cell, 2018, 47, 693-695.	3.1	3
7	Merlin/ERM proteins regulate growth factor-induced macropinocytosis and receptor recycling by organizing the plasma membrane:cytoskeleton interface. Genes and Development, 2018, 32, 1201-1214.	2.7	39
8	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Reports, 2015, 10, 1692-1707.	2.9	213
9	NF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin. Journal of Cell Biology, 2015, 211, 391-405.	2.3	54
10	Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship. Science Translational Medicine, 2014, 6, 237ra68.	5.8	203
11	ERM proteins at a glance. Journal of Cell Science, 2014, 127, 3199-204.	1.2	90
12	SPRED proteins provide a NF-ty link to Ras suppression. Genes and Development, 2012, 26, 1515-1519.	2.7	16
13	Merlin/ERM proteins establish cortical asymmetry and centrosome position. Genes and Development, 2012, 26, 2709-2723.	2.7	60
14	Contact inhibition (of proliferation) redux. Current Opinion in Cell Biology, 2012, 24, 685-694.	2.6	183
15	ERM proteins. Current Biology, 2012, 22, R784-R785.	1.8	10
16	Spatial regulation of receptor tyrosine kinases in development and cancer. Nature Reviews Cancer, 2012, 12, 387-400.	12.8	285
17	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics, Part A, 2012, 158A, 24-41.	0.7	101
18	Organizing the cell cortex: the role of ERM proteins. Nature Reviews Molecular Cell Biology, 2010, 11, 276-287.	16.1	884

#	Article	IF	Citations
19	Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes and Development, 2010, 24, 1718-1730.	2.7	233
20	The NF2 Tumor Suppressor, Merlin, Regulates Epidermal Development through the Establishment ofÂa Junctional Polarity Complex. Developmental Cell, 2010, 19, 727-739.	3.1	145
21	Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9767-9772.	3.3	54
22	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clinical Cancer Research, 2009, 15, 5032-5039.	3.2	74
23	Merlin and the ERM proteins â€“ regulators of receptor distribution and signaling at the cell cortex. Trends in Cell Biology, 2009, 19, 198-206.	3.6	179
24	Nf2/Merlin Regulates Hematopoietic Stem Cell Behavior by Altering Microenvironmental Architecture. Cell Stem Cell, 2008, 3, 221-227.	5.2	50
25	Localization to the Cortical Cytoskeleton Is Necessary for Nf2/Merlin-Dependent Epidermal Growth Factor Receptor Silencing. Molecular and Cellular Biology, 2008, 28, 1274-1284.	1.1	87
26	Neurofibromatosis. Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 191-216.	9.6	130
27	Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. Journal of Cell Biology, 2007, 177, 893-903.	2.3	316
28	Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical and Experimental Metastasis, 2007, 24, 69-78.	1.7	118
29	Microvilli defects in retinas of ezrin knockout mice. Experimental Eye Research, 2006, 82, 720-729.	1.2	76
30	A Mouse Model Recapitulating Molecular Features of Human Mesothelioma. Cancer Research, 2005, 65, 8090-8095.	0.4	152
31	Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes and Development, 2005, 19, 2265-2277.	2.7	238
32	Ezrinâ€¦ a metastatic detERMinant?. Cancer Cell, 2004, 5, 113-114.	7.7	97
33	Ezrin Is Essential for Epithelial Organization and Villus Morphogenesis in the Developing Intestine. Developmental Cell, 2004, 6, 855-864.	3.1	373
34	Merlin and ERM proteins: unappreciated roles in cancer development?. Nature Reviews Cancer, 2003, 3, 877-883.	12.8	175
35	DOCK4, a GTPase Activator, Is Disrupted during Tumorigenesis. Cell, 2003, 112, 673-684.	13.5	211
36	NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes and Development, 2003, 17, 1090-1100.	2.7	263

#	Article	IF	Citations
37	The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling. Developmental Cell, 2001, 1, 63-72.	3.1	311
38	Mouse models of neurofibromatosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2001, 1471, M73-M80.	3.3	12
39	Neurofibromatosis type II: mouse models reveal broad roles in tumorigenesis and metastasis. Trends in Molecular Medicine, 2000, 6, 252-253.	2.6	9
40	Tumor suppressor mutations in mice: the next generation. Current Opinion in Genetics and Development, 1998, 8, 304-310.	1.5	15
41	Regulation of the Neurofibromatosis Type 2 Tumor Suppressor Protein, Merlin, by Adhesion and Growth Arrest Stimuli. Journal of Biological Chemistry, 1998, 273, 7757-7764.	1.6	113
42	Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature, 1988, 331, 528-530.	13.7	1,105
43	The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid Î²-protein gene. Nature, 1987, 329, 156-157.	13.7	275
44	Neurofibromatoses. , 0, , 253-280.		1